Research work · 2020

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

Leisha A. Emens, Francisco J. Esteva, Mark J. Beresford, Cristina Saura, Michelino De Laurentiis, Sung‐Bae Kim, Seock‐Ah Im, Yifan Wang, Roberto Salgado, Aruna Mani, Jigna Shah, Chiara Lambertini, Haiying Liu, Sanne Lysbet de Haas, Monika Patre, Sherene Loi

The Lancet Oncology

DOI: 10.1016/s1470-2045(20)30465-4